Australia markets close in 3 hours 44 minutes
  • ALL ORDS

    7,714.60
    +24.90 (+0.32%)
     
  • ASX 200

    7,400.60
    +19.50 (+0.26%)
     
  • AUD/USD

    0.7429
    +0.0014 (+0.18%)
     
  • OIL

    82.14
    -0.30 (-0.36%)
     
  • GOLD

    1,769.00
    +3.30 (+0.19%)
     
  • BTC-AUD

    83,242.23
    -1,214.59 (-1.44%)
     
  • CMC Crypto 200

    1,443.22
    -8.41 (-0.58%)
     
  • AUD/EUR

    0.6386
    +0.0004 (+0.06%)
     
  • AUD/NZD

    1.0463
    +0.0003 (+0.03%)
     
  • NZX 50

    13,040.59
    +42.08 (+0.32%)
     
  • NASDAQ

    15,300.89
    +153.97 (+1.02%)
     
  • FTSE

    7,203.83
    -30.20 (-0.42%)
     
  • Dow Jones

    35,258.61
    -36.15 (-0.10%)
     
  • DAX

    15,474.47
    -112.89 (-0.72%)
     
  • Hang Seng

    25,409.75
    +78.75 (+0.31%)
     
  • NIKKEI 225

    29,127.76
    +102.30 (+0.35%)
     

Cycle Pharmaceuticals launches SAJAZIRTM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)

·4-min read

BOSTON, September 28, 2021--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle) is pleased to announce the launch of SAJAZIR™ (icatibant) Injection, a new treatment option for patients affected by Hereditary Angioedema (HAE) approved by the US Food and Drug Administration (FDA).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005566/en/

SAJAZIR™ is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

SAJAZIR™ patients will benefit from the newly created Cycle Vita™ support hub for patients with rare diseases (www.cyclevita.life).

Hereditary Angioedema (HAE) is a rare genetic potentially life-threatening disorder that results in recurring attacks of oedema (swelling) in various parts of the body, including the abdomen, extremities (hands/feet), genitals, face, and throat. It is estimated that there are more than 7,000 patients with HAE in the United States.

SAJAZIR™ is supplied in a prefilled syringe delivering 30 mg icatibant. Patients may self-administer SAJAZIR™ subcutaneously upon recognition of symptoms of a HAE attack after training under the guidance of a Healthcare Professional or a Registered Nurse from Cycle Vita™.

"The launch of SAJAZIR™ gives the HAE community an exciting new treatment option. Cycle understands the importance of providing product support to complement the impact of therapeutic products. SAJAZIR™ patients can take advantage of our newly launched product support hub, Cycle Vita™." said Zac Bohlen, Cycle’s VP of US Sales.

Cycle Vita™, the new product support platform launched by Cycle earlier this month, provides a range of product information and support to Healthcare Providers and rare disease patients across the United States who have been prescribed a Cycle medicine.

"Cycle Vita™ is an essential part of our core mission to better support patients with HAE and their families. We will appropriately guide patients through every stage of their journey by streamlining the enrollment and finance process and provide ongoing treatment support in addition to the expertise of the patient’s healthcare team." said John Reid, Director of patient hub services.

To find out more about SAJAZIR™, please visit www.cyclevita.life, or to find out more about Cycle Vita™, please visit www.cyclevita.life, or call (888) 360-8482.

IMPORTANT SAFETY INFORMATION
Laryngeal attacks can become life threatening. If you have an HAE attack of the throat (laryngeal attack), inject SAJAZIR™ and then go to the nearest hospital emergency room right away.

The most common side effects of SAJAZIR™ include:

  • redness, bruising, swelling, warmth, burning, itching, irritation, hives, numbness, pressure, or pain at the injection site

  • fever

  • too much of an enzyme called transaminase in your blood

  • dizziness

  • nausea

  • headache

  • rash

These are not all of the possible side effects of SAJAZIR™. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Tell your healthcare provider if you have any other medical conditions, if you are breastfeeding or plan to breastfeed, or if you are pregnant or planning to become pregnant. SAJAZIR™ has not been evaluated in pregnant or nursing women. You and your healthcare provider will decide if SAJAZIR™ is right for you.

If your symptoms continue or come back, you may repeat your SAJAZIR™ injection at least 6 hours apart. Do not use more than 3 doses of SAJAZIR™ in a 24-hour period.

Tiredness, drowsiness, and dizziness have been reported following the use of SAJAZIR™. If this occurs, do not drive a car, use machinery, or do anything that needs you to be alert.

To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals at 1-800-836-4380, or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch.

For more detailed information, please refer to the Full Prescribing Information and visit www.cyclevita.life/SAJAZIR for more information about SAJAZIR™.

SAJAZIR™ and Cycle Vita™ are trademarks of Cycle Pharmaceuticals Limited in the United States.

US-SJR-2100017 September 2021

About Cycle Vita™
Cycle Vita™ is the product support platform created by Cycle Pharmaceuticals, with the goal of providing product support that mirrors and amplifies the life-changing effects of Cycle treatments. We provide clinical, financial* and emotional product support to rare disease patients. The Cycle Vita™ hub is based out of Boston, Massachusetts. For more information, please visit www.cyclevita.life, or call (888) 360-8482, and follow us on Facebook.

*Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only.

About Cycle Pharmaceuticals
Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and product support to the under-served rare disease patient community. We focus on rare metabolic, immunological, and neurological genetic conditions. Cycle is headquartered in Cambridge, UK and has offices in Boston, Massachusetts. For more information, please visit www.cyclepharma.com and follow us on Twitter, LinkedIn, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005566/en/

Contacts

Cycle Pharmaceuticals
Chikai Lai, Vice President, Operations US
Tel: +44 1223 354 118
Marketing@cyclepharma.com
Email: info@cyclepharma.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting